CN101129464A - Traditional Chinese medicine composition for qi-benefitting blood circulation promoting and eliminating stasis activating meridian and processes for producing same - Google Patents
Traditional Chinese medicine composition for qi-benefitting blood circulation promoting and eliminating stasis activating meridian and processes for producing same Download PDFInfo
- Publication number
- CN101129464A CN101129464A CNA2007101452928A CN200710145292A CN101129464A CN 101129464 A CN101129464 A CN 101129464A CN A2007101452928 A CNA2007101452928 A CN A2007101452928A CN 200710145292 A CN200710145292 A CN 200710145292A CN 101129464 A CN101129464 A CN 101129464A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- moschus
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a Chinese medicinal composition having functions of resolving phlegm, relieving cough, promoting blood flow, dispelling stasis and preparing method, wherein the Chinese medicinal composition is prepared from astragalus root, earthworm, leeches, root of red rooted saliva, kudzu vine root, musk, boneol and buffalo horn concentrated powder through steps of disintegrating, water extracting, concentrating, drying and disintegrating into fines, mixing the fines with concentrated buffalo horn powder and borneol homogenously.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, be specifically related to the Chinese medicine composition that a kind of benefiting QI for activating blood circulation, blood stasis dispelling are promoted blood circulation, can be used for the treatment of coronary heart disease with qi deficiency and blood stasis and cerebral infarction.In addition, the invention still further relates to the preparation method of this Chinese medicine composition and in the application of preparation treatment coronary heart disease, cerebral infarction medicine.
Background technology
Cardio-cerebralvascular diseases is one of worldwide three generally acknowledged big diseases of World Health Organization (WHO), also is the topmost disease of harm humans life and health.According to The World Health Organization's statistics, the whole world has 1,200 ten thousand people to die from cardiovascular and cerebrovascular disease every year approximately, and the morbidity of China's cardiovascular and cerebrovascular disease is just becoming ascendant trend with mortality rate.China has 3,000,000 people to die from cardiovascular and cerebrovascular disease every year approximately according to statistics.Wherein coronary heart disease stable type fatigue angina pectoris and cerebral infarction are disease types the most representative in the cardiovascular and cerebrovascular disease.
Angina pectoris belongs to motherland's medical science " thoracic obstruction ", " pained " category, and pathogenic characteristic is a deficiency in origin and excess in superficiality.Insufficiency of heart-QI and deficiency of heart-yin are this, and expectorant, the stasis of blood are become mark mutually.The deficiency of vital energy, the deficiency of YIN, four key links that expectorant is turbid, blood stasis has constituted thoracic obstruction pathogenesis.Nourishing-to-relaxing is emphasized in treatment by Chinese herbs, and invigorating middle warmer residence is logical, and through-supplementation is conceived to the adjusting of allomeric function, and reaching gas, to be full of blood capable, the blood vessels tonneau.Effective Chinese patent medicine that the emergency of many treatment coronary heart disease is arranged is now clinically worked as angina pectoris and is relaxed after the use, then need to use instead other medicines, should not take these medicines for a long time continuously.Because though these medicine analgesic effects are rapid, many with the QI and blood that consumes the body of hurting sb.'s feelings for a long time with meeting, unfavorable to the state of an illness.
Cerebral infarction belongs to Chinese medicine apoplexy category, how to narrow down because of hypertension, diabetes, hyperlipidemia etc. cause cerebral arteries regression, sclerosis, tube chamber is tortuous, the tube wall became uneven, blood viscosity increases, and platelet aggregation rate strengthens, the blood self-solidifying forms thrombosis, artery-clogging causes the cerebral blood circulation obstacle, the cerebral cell ischemia anoxia, cranial nerve impaired and burst hemiplegia, facial hemiparalysis, refreshingly know unconsciousness, the match of stiff tongue speech, hemianesthesia etc., morbidity suddenly, the course of disease is long, cure rate is low.The traditional Chinese medical science generally adopts method symptomatic treatments such as blood circulation promoting and blood stasis dispelling, dredging the meridian, alleviated the state of an illness to a certain extent, but therapeutic effect is undesirable, all can not reach the purpose of curing fully, and many sequela that occur together.
Summary of the invention
The object of the present invention is to provide a kind of promote blood circulation Chinese medicine composition of curative effect of benefiting QI for activating blood circulation, blood stasis dispelling that has, this Chinese medicine composition is used for the treatment of coronary heart disease and cerebral infarction good effect, and is safe and reliable.
Another object of the present invention is to provide the preparation method of this Chinese medicine composition.
The present invention also aims to the application of this Chinese medicine composition in the medicine of preparation treatment coronary heart disease with qi deficiency and blood stasis and cerebral infarction.
The angina pectoris traditional Chinese medical science is called " thoracic obstruction ", and it is much more sick because of due to the stagnation of blood stasis heart arteries and veins." apoplexy " is the names of disease of tcm of cerebrovascular accident, and it is much more sick because of hyperactive liver-YANG causing syndrome of liver-wind, revolves on the wind-phlegm, due to the stagnation of blood stasis venation.This shows that apoplexy, the thoracic obstruction be many stagnation of blood stasis venation all, venation numbness resistance and heart and brain lose supports, so the multiple symptom of clinical appearance.The traditional Chinese medical science is thought, " qi being the governor of blood ", it is power that the operation of blood relies on gas, thus benefiting QI for activating blood circulation better blood stasis dispelling promote blood circulation.Because the two has identical pathogenesis, thus treatment all can benefiting QI for activating blood circulation, the become silted up refreshment of promoting blood circulation, have one's ideas straightened out of dispelling is method.The present invention is an experience of using for reference year clinical treatment coronary heart disease surplus the traditional Chinese medical science 30, angina pectoris and apoplexy, analyses scientifically and the compound Chinese medicinal preparation of screening in conjunction with the modern Chinese medicine theory.Through clinical verification, to apoplexy, hemiplegia, slurred speech, numb hand and foot, and disease such as pain in the chest due to obstruction of QI has special efficacy.
The objective of the invention is to be achieved through the following technical solutions:
The Chinese medicine composition that benefiting QI for activating blood circulation of the present invention, blood stasis dispelling are promoted blood circulation is to be made by the raw material of following weight parts:
100～300 parts of the Radixs Astragali, 50～300 parts of Pheretimas, 10～100 parts of Hirudos, 50～300 parts of Radix Salviae Miltiorrhizaes, 50～300 parts of Radix Puerariaes, 0.05～1 part in Moschus, 1～10 part of Borneolum Syntheticum, 10～100 parts of Pulvis Cornus Bubali Concentratuss.
Preferred weight part of preparation Chinese medicine composition of the present invention is:
150～250 parts of the Radixs Astragali, 80～130 parts of Pheretimas, 25～45 parts of Hirudos, 150～250 parts of Radix Salviae Miltiorrhizaes, 100～200 parts of Radix Puerariaes, 0.1～0.3 part in Moschus, 3～5 parts of Borneolum Syntheticums, 30～40 parts of Pulvis Cornus Bubali Concentratuss.
Optimum weight part of preparation Chinese medicine composition of the present invention is:
215 parts of the Radixs Astragali, 110 parts of Pheretimas, 35 parts of Hirudos, 180 parts of Radix Salviae Miltiorrhizaes, 140 parts of Radix Puerariaes, 0.2 part in Moschus, 4 parts of Borneolum Syntheticums, 35 parts of Pulvis Cornus Bubali Concentratuss.
Moschus during Chinese medicine composition of the present invention is raw materials used can be the artificial Moschus.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production also can restrain and be unit, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
Medicine of the present invention can be made various conventional peroral dosage forms with above-mentioned raw materials and pharmaceutically acceptable carrier or excipient.
Described medicine acceptable carrier can be but be not limited to: starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, cyclodextrin, beta-schardinger dextrin-etc.
Chinese medicine preparation of the present invention can be but be not limited to: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid etc.Preparation of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc., more preferably capsule.
Preparation of the present invention is determined usage and dosage according to patient's situation in use.This medicament specification is every 0.3g, and is oral, one time 4,3 times on the one, adult (50kg) day therapeutic dose is 3.6g, i.e. the 0.072g/kg body weight.
The present invention also provides the preparation method of above-mentioned Chinese medicine composition, comprises the steps:
1), take by weighing raw material by following weight portion:
100～300 parts of the Radixs Astragali, 50～300 parts of Pheretimas, 10～100 parts of Hirudos, 50～300 parts of Radix Salviae Miltiorrhizaes, 50～300 parts of Radix Puerariaes, 0.05～1 part in Moschus, 1～10 part of Borneolum Syntheticum, 10～100 parts of Pulvis Cornus Bubali Concentratuss;
2) it is standby Moschus to be ground into fine powder, and Pheretima, that Hirudo powder is broken into fine powder is standby;
3) Radix Astragali, Radix Salviae Miltiorrhizae, Radix Puerariae three flavors are given as one thinks fit cataclasm, add water 6-10 and doubly measure the decoction secondary, decocted 1-3 hour at every turn, gradation filters, merging filtrate, and to be concentrated into relative density in 60-100 ℃ be 1.20～1.25 extractum, and drying, it is standby to be ground into fine powder;
4) above each standby fine powder and Pulvis Cornus Bubali Concentratus, Borneolum Syntheticum are merged, mixing is made described Chinese medicine composition.
Wherein, step 2) and 3) fine powder of gained all can wherein be no less than 95% and can pass through to sieve (100 order) No. 6 by No. 5 sieves (80 order).
The best thickening temperature of step 3) is 80 ℃ in the above-mentioned preparation method.
Used Moschus can be the artificial Moschus in the preparation method of above-mentioned Chinese medicine composition.
Each raw material components of the present invention is that wherein the Radix Astragali, Radix Salviae Miltiorrhizae are monarch through repeated screening and science compatibility gained, and Pheretima, Hirudo, Radix Puerariae are minister; Cornu Bubali, Moschus, Borneolum Syntheticum are assistant; And Moschus is held concurrently and to be messenger drug.The mutual compatibility of all medicines, monarch is orderly, and residence is mended in rushing down, reinforcement and elimination in combination, benefiting QI for activating blood circulation and not blocking, blood stasis dispelling is promoted blood circulation and is not felt frustrated, and plays benefiting QI for activating blood circulation, blood stasis dispelling promote blood circulation, the have one's ideas straightened out effect of refreshment altogether.
Chinese medicine composition of the present invention has the curative effect that benefiting QI for activating blood circulation, blood stasis dispelling are promoted blood circulation, and can be used for preparing the medicine of treatment coronary heart disease with qi deficiency and blood stasis and cerebral infarction.
Medicine of the present invention is mainly used in benefiting QI for activating blood circulation, blood stasis dispelling is promoted blood circulation, and for the angina pectoris of treatment coronary heart disease with qi deficiency and blood stasis, diseases such as cerebral infarction at restoration stage truly have curative effect.From the clinical practice situation, medicine of the present invention is obvious to the stroke patient of cerebral infarction at restoration stage and the thoracic obstruction patient's of coronary heart disease stable type angina of effort etc. therapeutic effect, and total effective rate reaches 96.7% and 90.0%.Also do not find anaphylaxis and toxic and side effects in the clinical trial, this product determined curative effect is described, avirulence, clinical drug safety.Medicine of the present invention can reach good effect in treatment clinical course, do not need the other drug auxiliary treatment, has reduced drug combination.
In order to show the therapeutic effect of medicine of the present invention, the present invention has carried out animal experiment and clinical observation test.Used medicine of the present invention is the capsule that adopts embodiment 4 to make in the test, is called imperial red capsule for freeing collateral vessels, and specification is every 0.3g, oral one time 3,3 times on the one, 8 weeks were a course of treatment.Adult (50kg) day therapeutic dose is 2.7g, i.e. the 0.054g/kg body weight.
Take by weighing the imperial red capsule for freeing collateral vessels Chinese medicine powder of constant weight during animal experiment, put into mortar and add appropriate amount of starch and stick with paste and to grind well, the limit adds the waterside grinds, and is made into the imperial red collateral dredging suspension of desired concn at last with distilled water.Dosage is by the red capsule for freeing collateral vessels medicated powder re-computation of animal per kilogram of body weight dragon.Positive control drug is the troxerutin sheet, and bio-pharmaceuticals factory in Jiamusi produces, lot number 940312, the heavy 0.1g of substrate, oral, one time 2 to 3,3 times on the one.The inventor has carried out main pharmacodynamics test, comprising cerebral ischemia test, to the influence of rat platelet aggregation function, to the thrombotic influence of rat experiment, to clotting time influence, myocardial ischemia test, to the influence of hyperlipidemia rats serum total cholesterol TC, triglyceride TG and to the influence of rat acute experimental hypertension, find imperial red capsule for freeing collateral vessels and troxerutin sheet there are no significant in these areas difference, and some curative effect is better than the troxerutin sheet.
The red capsule for freeing collateral vessels of dragon is through the gastric infusion approach, rat brain content and cerebral index increase there is tangible antagonism, also can obviously prolong breathing the time of white mice, energy significant prolongation rat blood examination formation time has significant inhibitory effect to the inductive platelet aggregation of ADP.Have and accelerate the Electrocardiographic recovery of guinea pig myocardium acute ischemia due to the pituitrin, reduce rat heart muscle acute ischemia positive rate due to the pituitrin; Improve the survival rate under the mice hypobaric hypoxia condition; Obviously reduce the whole oxygen consumption of mice; Prolong clotting time of mice and rat blood plasma recalcification time; Cholesterol reducing, triglyceride and the effect that brings high blood pressure down.
Show that by above-mentioned results of pharmacodynamic test imperial red capsule for freeing collateral vessels has anti-cerebral ischemia, antiplatelet aggregation, antithrombotic formation, anticoagulation, resist myocardial ischemia, effect such as anoxia enduring, blood fat reducing, blood pressure lowering.Cerebral ischemia has protective effect to rat experiment, pituitrin is brought out Cavia porcellus and Acute Myocardial Ischemia in Rats also have protective effect due to the coronary vasospasm.
For further specifying the beneficial effect of medicine of the present invention, below clinical trial by medicine of the present invention further prove the good result of this medicine to coronary heart disease and cerebral infarction therapy.
1. medicine of the present invention is used for the treatment of the stroke patient 400 routine clinical observation tests of cerebral infarction at restoration stage.
Adopt parallel check experiment scheme at random, carry out the blind method of list and observe.Selecting stroke patient 400 examples, all is cerebral infarction at restoration stage, and Chinese medical discrimination is apoplex involving the channels and collaterals syndrome of blood stasis due to qi deficiency person, is divided into observation group and matched group at random.Observation group gives medicine dragon of the present invention red capsule for freeing collateral vessels, and matched group is given the control drug BUCHANG NAOXINTONG JIAONANG, and dosage regimen is oral each 4, and every day 3 times, 8 weeks were a course of treatment.
Observation group's 300 examples in the test, wherein male 191 examples, women 109 examples; 45～69 years old age, 57.20 years old mean age; 2 weeks of the course of disease～half a year, average 2.6 months; 100 examples that the state of an illness is slight, moderate 128 examples, severe 72 examples; Outpatient service 201 examples, 99 examples of being in hospital.Matched group 100 examples in the test, wherein male 64 examples, women 36 examples; 44～69 years old age, 57.95 years old mean age; 2 weeks of the course of disease～half a year, average 2.4 months; 33 examples that the state of an illness is slight, moderate 53 examples, severe 14 examples; Outpatient service 72 examples, 28 examples of being in hospital.From distribution situations such as two groups of ages, sex, the state of an illness, the course of disease, case sources, all there is not explicitly difference, have comparability.
The apoplexy efficacy assessment standard is represented with percent for adopting nimodipine method [integration before (integration before the treatment-treatment back integration) ÷ treatment] * 100%, is carried out the level Four efficacy evaluation.
(1) basic rehabilitation: 〉=85%;
(2) produce effects: 〉=50%,＜85%;
(3) effective: 〉=20%,＜50%;
(4) invalid:＜20%.
General curative effect is observed and is seen Table 1
Table 1 liang group general curative effect relatively
| Group | The example number | Basic rehabilitation | Produce effects | Effectively | Invalid | Total effective rate | Obvious effective rate |
| Observation group | 300 | 81 | 124 | 85 | 10 | 96.7％ | 68.33％ |
| Matched group | 100 | 21 | 25 | 47 | 7 | 93.0％ | 46.00％ |
By table 1 as seen, relatively analyze through Ridit for two groups, significant difference is arranged, P＜0.05 illustrates that observation group's general curative effect is better than matched group.Do not find untoward reaction in the test, visible imperial red capsule for freeing collateral vessels has better curative effect to the stroke patient of treatment cerebral infarction at restoration stage, and safe and reliable, but life-time service.
2. medicine of the present invention is used for the treatment of thoracic obstruction patient's 120 routine clinical observation tests of coronary heart disease stable type angina of effort
Adopt parallel check experiment scheme at random, carry out the blind method of list and observe.Selecting thoracic obstruction patient 120 examples, all is coronary heart disease stable type fatigue angina pectoris, is divided into observation group and matched group at random.Observation group gives medicine dragon of the present invention red capsule for freeing collateral vessels, and matched group is given contrast medicine BUCHANG NAOXINTONG JIAONANG, and dosage regimen is each 4, and every day 3 times, oral 8 weeks are a course of treatment.Observation group's 80 examples in the clinical trial, male 45 examples, women 35 examples; 28～65 years old age, 54.64 years old mean age; The course of disease 1 month～15 years, average 4.66; 31 examples that the state of an illness is slight, moderate 49 examples; Outpatient service 23 examples, 57 examples of being in hospital.Matched group 40 examples, wherein male 25 examples, women 15 examples; 34～65 years old age, 54.43 years old mean age; The course of disease 1.5 months～14 years, average 4.31; 14 examples that the state of an illness is slight, moderate 26 examples; Outpatient service 6 examples, 34 examples of being in hospital.From distribution situations such as two groups of ages, sex, the state of an illness, the course of disease, case sources, no significant difference has comparability.
Tcm syndrome efficacy assessment standard:, and, formulate the level Four criterion of therapeutical effect with reference to the variation of syndrome integration according to the variation of syndrome weight grade before and after the treatment.
(1) clinical rehabilitation: primary symptom and double disease all disappear, and the syndrome integration drops to 0.
(2) produce effects: disease weight grade decline secondary, or the syndrome integration (comprises 2/3) than reducing before treating more than 2/3.
(3) effective: disease weight grade decline one-level, or the syndrome integration reduces before treating and (comprises 1/3) more than 1/3, but deficiency.
(4) invalid: symptom and sign does not have improvement.
Table 2 liang group therapeutic effect of syndrome relatively
| Group | The example number | Clinical rehabilitation | Produce effects | Effectively | Invalid | Total effective rate | Obvious effective rate |
| Observation group | 80 | 21 | 34 | 22 | 3 | 96.3％ | 68.8％ |
| Matched group | 40 | 7 | 10 | 20 | 3 | 92.5％ | 42.5％ |
By table 2 as seen, relatively analyze through Ridit for two groups, notable difference is arranged, P＜0.05 illustrates that observation group's therapeutic effect of syndrome is better than matched group.
The curative effect to treat angina pectoris evaluation criteria:
(1), minor angina
1) produce effects: transference cure or basic the disappearance.
2) effective: pain attack times, degree and persistent period have obviously and alleviate.
3) invalid: symptom is preceding identical with treatment substantially.
4) increase the weight of: pain attack times, degree and persistent period increase the weight of to some extent.
(2), moderate angina pectoris
1) produce effects: transference cure or basic the disappearance.
2) effective: sx is to the standard of " slightly ".
3) invalid: symptom is preceding identical with treatment substantially.
4) increase the weight of: pain attack times, degree and persistent period, all increase the weight of to some extent.
Curative effect to treat angina pectoris is observed and is seen Table 3
Table 3 liang group curative effect to treat angina pectoris relatively
| Group | The example number | Produce effects | Effectively | Invalid | Increase the weight of | Total effective rate | Obvious effective rate |
| Observation group | Slightly: 31 moderates: 49 add up to: 80 | 16 20 36 | 13 23 36 | 2 6 8 | 0 0 0 | 93.6％ 87.8％ 90.0％ | 51.6％ 40.8％ 45.0％ |
| Matched group | Slightly: 14 moderates: 26 add up to: 40 | 5 5 10 | 7 16 23 | 2 5 7 | 0 0 0 | 85.7％ 80.8％ 82.5％ | 35.75％ 19.2％ 25.0％ |
By table 3 as seen, observation group's curative effect to treat angina pectoris is better than matched group, analyzes P＜0.05 through Ridit, and significant difference is arranged.
Also ECG curative effect after two groups of medications is observed simultaneously, the total effective rate that draws observation group is 62.5%, the total effective rate of matched group is 50.0%, thereby further draw, the red capsule for freeing collateral vessels of dragon has better curative effect to the anginal thoracic obstruction patient of treatment coronary heart disease stable type fatigue, effect is better than matched group, does not also find untoward reaction, is the medicine that is worth of widely use clinically.
The specific embodiment
Further specify the present invention by the following examples, but therefore do not limit the present invention in the described scope of embodiments.
Embodiment 1
Radix Astragali 100g, Pheretima 50g, Hirudo 10g, Radix Salviae Miltiorrhizae 50g, Radix Puerariae 50g,
Moschus 0.05g, Borneolum Syntheticum 1g, Pulvis Cornus Bubali Concentratus 10g.
It is standby that the artificial Moschus is ground into fine powder; Pheretima, that Hirudo powder is broken into fine powder is standby; The Radix Astragali, Radix Salviae Miltiorrhizae, Radix Puerariae three flavors are given as one thinks fit cataclasm, add 8 times of amounts of water and decoct secondary, decocted 1.5 hours at every turn, gradation filters, merging filtrate, and to be concentrated into relative density in 80 ℃ be 1.20～1.25 extractum, drying is ground into fine powder; Above standby fine powder and Pulvis Cornus Bubali Concentratus, Borneolum Syntheticum are merged, and mixing is made capsule.
Embodiment 2
Radix Astragali 300g, Pheretima 300g, Hirudo 100g, Radix Salviae Miltiorrhizae 300g, Radix Puerariae 300g artificial Moschus 1.0g, Borneolum Syntheticum 10g, Pulvis Cornus Bubali Concentratus 100g.
Preparation method is with embodiment 1.
Embodiment 3
Radix Astragali 200g, Pheretima 175g, Hirudo 55g, Radix Salviae Miltiorrhizae 175g, Radix Puerariae 175g, artificial Moschus 0.5g, Borneolum Syntheticum 5.5g, Pulvis Cornus Bubali Concentratus 55g.
Preparation method is with embodiment 1.
Embodiment 4
Radix Astragali 215g, Pheretima 110g, Hirudo 35g, Radix Salviae Miltiorrhizae 180g, Radix Puerariae 140g, artificial Moschus 0.2g, Borneolum Syntheticum 4g, Pulvis Cornus Bubali Concentratus 35g.
Preparation method is with embodiment 1.
Claims (10)
1. one kind has the promote blood circulation Chinese medicine composition of curative effect of benefiting QI for activating blood circulation, blood stasis dispelling, it is characterized in that it is to be made by the raw material of following weight parts:
100～300 parts of the Radixs Astragali, 50～300 parts of Pheretimas, 10～100 parts of Hirudos, 50～300 parts of Radix Salviae Miltiorrhizaes, 50～300 parts of Radix Puerariaes, 0.05～1 part in Moschus, 1～10 part of Borneolum Syntheticum, 10～100 parts of Pulvis Cornus Bubali Concentratuss.
2. according to the Chinese medicine composition of claim 1, it is characterized in that the weight portion of each raw material is:
150～250 parts of the Radixs Astragali, 80～130 parts of Pheretimas, 25～45 parts of Hirudos, 150～250 parts of Radix Salviae Miltiorrhizaes, 100～200 parts of Radix Puerariaes, 0.1～0.3 part in Moschus, 3～5 parts of Borneolum Syntheticums, 30～40 parts of Pulvis Cornus Bubali Concentratuss.
3. according to the Chinese medicine composition of claim 1, it is characterized in that the weight portion of each raw material is:
215 parts of the Radixs Astragali, 110 parts of Pheretimas, 35 parts of Hirudos, 180 parts of Radix Salviae Miltiorrhizaes, 140 parts of Radix Puerariaes, 0.2 part in Moschus, 4 parts of Borneolum Syntheticums, 35 parts of Pulvis Cornus Bubali Concentratuss.
4. according to each described Chinese medicine composition of claim 1-3, it is characterized in that described Moschus is the artificial Moschus.
5. the capsule that makes by each described Chinese medicine composition of claim 1-3.
One kind prepare have benefiting QI for activating blood circulation, the method for Chinese medicine composition that blood stasis dispelling is promoted blood circulation curative effect, this method comprises the steps:
1), take by weighing raw material by following weight portion:
100～300 parts of the Radixs Astragali, 50～300 parts of Pheretimas, 10～100 parts of Hirudos, 50～300 parts of Radix Salviae Miltiorrhizaes, 50～300 parts of Radix Puerariaes, 0.05～1 part in Moschus, 1～10 part of Borneolum Syntheticum, 10～100 parts of Pulvis Cornus Bubali Concentratuss;
2) it is standby Moschus to be ground into fine powder, and Pheretima, that Hirudo powder is broken into fine powder is standby;
3) Radix Astragali, Radix Salviae Miltiorrhizae, Radix Puerariae three flavors are given as one thinks fit cataclasm, add water 6-10 and doubly measure the decoction secondary, decocted 1-3 hour at every turn, gradation filters, merging filtrate, and to be concentrated into relative density in 60-100 ℃ be 1.20～1.25 extractum, and drying, it is standby to be ground into fine powder;
4) above each standby fine powder and Pulvis Cornus Bubali Concentratus, Borneolum Syntheticum are merged, mixing is made described Chinese medicine composition.
7. the preparation method of Chinese medicine composition according to claim 6 is characterized in that described Moschus is the artificial Moschus.
8. the preparation method of Chinese medicine composition according to claim 6 is characterized in that described fine powder all can be by No. 5 sieves, and wherein being no less than 95% can be by No. 6 sieve.
9. the preparation method of Chinese medicine composition according to claim 6, the thickening temperature that it is characterized in that step 3) is 80 ℃.
10. according to the application of each described Chinese medicine composition of claim 1-3 in preparation treatment coronary heart disease with qi deficiency and blood stasis and cerebral infarction medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101452928A CN101129464A (en) | 2007-08-21 | 2007-08-21 | Traditional Chinese medicine composition for qi-benefitting blood circulation promoting and eliminating stasis activating meridian and processes for producing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101452928A CN101129464A (en) | 2007-08-21 | 2007-08-21 | Traditional Chinese medicine composition for qi-benefitting blood circulation promoting and eliminating stasis activating meridian and processes for producing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101129464A true CN101129464A (en) | 2008-02-27 |
Family
ID=39126974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101452928A Pending CN101129464A (en) | 2007-08-21 | 2007-08-21 | Traditional Chinese medicine composition for qi-benefitting blood circulation promoting and eliminating stasis activating meridian and processes for producing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101129464A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101849967A (en) * | 2010-06-02 | 2010-10-06 | 苏店第二卫生所 | Medicament for curing apoplexy hemiplegy sequela and preparation method thereof |
| CN102824406A (en) * | 2012-09-24 | 2012-12-19 | 南京正亮医药科技有限公司 | Application of longdan tongluo capsule in preparation of pharmaceuticals for inhibiting MJ cell proliferation |
| CN104116779A (en) * | 2014-07-30 | 2014-10-29 | 哈尔滨圣泰生物制药有限公司 | Traditional Chinese medicine composition for treating qi deficiency and blood stasis type cardiovascular and cerebrovascular diseases as well as capsule and preparation method thereof |
| CN105327059A (en) * | 2015-11-29 | 2016-02-17 | 杨春风 | Traditional Chinese medicinal composition for treating coronary heart disease |
| CN114601910A (en) * | 2022-04-14 | 2022-06-10 | 黎泯渲 | Traditional Chinese medicine formula for treating thrombotic stroke |
-
2007
- 2007-08-21 CN CNA2007101452928A patent/CN101129464A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101849967A (en) * | 2010-06-02 | 2010-10-06 | 苏店第二卫生所 | Medicament for curing apoplexy hemiplegy sequela and preparation method thereof |
| CN102824406A (en) * | 2012-09-24 | 2012-12-19 | 南京正亮医药科技有限公司 | Application of longdan tongluo capsule in preparation of pharmaceuticals for inhibiting MJ cell proliferation |
| CN102824406B (en) * | 2012-09-24 | 2016-01-27 | 汪蕾 | The red capsule for freeing collateral vessels of dragon suppresses the application in MJ cell proliferation in preparation |
| CN104116779A (en) * | 2014-07-30 | 2014-10-29 | 哈尔滨圣泰生物制药有限公司 | Traditional Chinese medicine composition for treating qi deficiency and blood stasis type cardiovascular and cerebrovascular diseases as well as capsule and preparation method thereof |
| CN104116779B (en) * | 2014-07-30 | 2018-03-09 | 哈尔滨圣泰生物制药有限公司 | A kind of Chinese medicine composition and its capsule and preparation method with anti-cerebral ischemia and function of resisting myocardial ischemia |
| CN105327059A (en) * | 2015-11-29 | 2016-02-17 | 杨春风 | Traditional Chinese medicinal composition for treating coronary heart disease |
| CN114601910A (en) * | 2022-04-14 | 2022-06-10 | 黎泯渲 | Traditional Chinese medicine formula for treating thrombotic stroke |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100457176C (en) | Chinese medicinal preparation for curriculum of physical and fatigue reducing | |
| CN100382839C (en) | Chinese-medicinal composition for treating coronary heart disease | |
| CN101711847B (en) | Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis | |
| CN101708237B (en) | Medicinal composition used for tonifying qi and invigorating pulse, preparation method thereof and application thereof | |
| CN101129464A (en) | Traditional Chinese medicine composition for qi-benefitting blood circulation promoting and eliminating stasis activating meridian and processes for producing same | |
| CN101347557B (en) | Medicament composition for refreshment and intelligence development and preparation and use thereof | |
| CN100333750C (en) | Chinese medicinal preparation for treating qi obstruction in chest and heart palpitation and its preparation process | |
| CN101584796B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating melancholia | |
| CN101366903B (en) | Traditional Chinese medicine composition for treating climacteric syndrome | |
| CN101279034B (en) | Combined Chinese medicament for curing diabetic with combined internal and external therapies and preparation thereof | |
| CN100455313C (en) | Chinese medicine for treating cardiovascular and cerebrovascular disease | |
| CN101745048B (en) | Medicine for treating type II diabetes and resisting aging | |
| CN101744912A (en) | Traditional Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1111054C (en) | Medicine for treating apoplexy and its preparing process | |
| CN101637556B (en) | Pharmaceutical composition for treating heart disease and preparation method thereof | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN102266481B (en) | Chinese medicinal preparation for treating chronic cerebral circulation insufficiency | |
| CN101099836B (en) | Traditional Chinese medicine composition for treating ischemic apoplexy and preparation process thereof | |
| CN101130009A (en) | Proprietary Chinese medicine for treating atherosclerosis of cardio-cerebral arteria and method for preparing the same | |
| CN103385963A (en) | Chinese medicine preparation for treating angina pectoris caused by coronary heart disease | |
| CN103735793B (en) | A kind ofly treat Chinese medicine of numb limbs and tense tendons after diabetes patient's apoplexy and preparation method thereof | |
| CN103142696B (en) | Vessel-invigorating and life-prolonging soup and preparation method thereof | |
| CN1242801C (en) | Medicinal composition for treating coronary heart disease and angine pectoris | |
| CN104958751A (en) | Foot bath composition for treating hypotension and preparation method of foot bath composition | |
| CN1256963C (en) | Antifatigue medicine and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080227 |